Asia · Financial press · SCMP Business
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Detailed summary
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.scmp.com)

